Analgesic Efficacy of Adding Sciatic Blockade to the 3-in-1 Block Following Total Knee Arthroplasty: A Meta-analysis
AuthorHolmes, Johnnie M.
MetadataShow full item record
AbstractBackground: Total knee arthroplasty (TKA) is one of the most common orthopedic procedures performed. It is also invasive and is associated with severe postoperative pain. The 3-in-1 block has been repeatedly demonstrated to provide effective postoperative analgesia. However, adding sciatic blockade to the 3-in-1 has become a growing practice as a result of residual pain to the posterior knee, although the additional benefit is unknown particularly in light of the potential risks. Purpose: To examine the analgesic efficacy and associated adverse events of adding sciatic blockade to the 3-in-1 block compared to the 3-in-1 alone for postoperative analgesia following TKA. Methods: A meta-analysis was conducted on relevant articles from 1993 to 2010. Methodological rigor was applied to each of the analytical procedures including: evaluation of between-study heterogeneity, pooling effects, subgroup analyses, sensitivity analysis, and assessment of publication bias. Results: Nine studies representing 1827 subjects were included. Pain outcomes were measured with the visual analog scale both at rest (VASr) and dynamic (VASd) and reported as the weighted mean difference (WMD). The addition of sciatic blockade demonstrated improved postoperative analgesia with the greatest effects up to 24 hours postoperatively: early (6-8hr) VASr WMD -2.039 (95% CI: -2.718, -1.360); 12hr VASr WMD -1.491 (95% CI: -2.174, -0.808); 24hr VASr WMD -0.767 (95% CI: -1.114, -0.421); 24hr VASd WMD -0.671 (95% CI: -1.301, -0.041). The 24hr opioid consumption was also lower [WMD -10.237 (95% CI: -20.029, -0.444)]. After 24 hours, effects were small and/or not significant. There was also a statistically significant advantage in maximum knee flexion on POD3 [WMD -7.102 (95% CI: -11.864, -2.339)]. A lack of consistent reporting precluded quantitative analysis on adverse events. Conclusion: Findings support the use of peripheral nerve blocks for postoperative analgesia following TKA. The addition of sciatic blockade appears to offer greater analgesic efficacy than a 3-in-1 block alone but only in the early postoperative period. However, until an accurate estimate of associated adverse events can be unveiled, the addition of a sciatic block cannot be recommended for all patients following TKA. It should, however, be considered in the postoperative period for those patients who continue to experience substantial pain to the posterior aspect of the knee on a case-by-case basis.
DescriptionUniversity of Maryland, Baltimore. Nursing. Ph.D. 2010
Keyword3-in-1 nerve block
femoral nerve block
peripheral nerve block
sciatic nerve block
total knee arthroplasty
Arthroplasty, Replacement, Knee
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/894
Showing items related by title, author, creator and subject.
Therapeutic and transmission-blocking efficacy of dihydroartemisinin/ piperaquine and chloroquine against Plasmodium vivax Malaria, CambodiaPopovici, J.; Vantaux, A.; Primault, L. (Centers for Disease Control and Prevention (CDC), 2018)We assessed the efficacy of standard 3-day courses of chloroquine and dihydroartemisinin/piperaquine against Plasmodium vivax malaria. Compared with chloroquine, dihydroartemisinin/piperaquine was faster in clearing asexual P. vivax parasites and blocking human-to-mosquito transmission. This drug combination was also more effective in preventing potential recurrences for >2 months. Copyright 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
Characterization of novel retinoic acid metabolism blocking agents (RAMBAs) in breast cancer model systemsPatel, Jyoti B.; Njar, Vincent (2005)All-trans-retinoic acid (ATRA) and other retinoids, potent modulators of a variety of important cellular functions are effective in prevention and therapy of many cancers including breast cancer. Increased metabolism of ATRA by ATRA inducible cytochrome P450 enzymes present in different cells including cancer cells is one of the reasons for the emergence of ATRA resistance and hampering its clinical use. Additionally, high therapeutic doses of ATRA have adverse effects and are not recommended.Retinoic acid metabolism blocking agents (RAMBAs) prevent rapid metabolism of ATRA. Use of RAMBAs is an emerging approach to increase the endogenous levels and thus potentiate the effect of ATRA without administering high exogenous doses. The objective of this project was to investigate the in vitro and in vivo role of novel C-4 azolyl RAMBAs rationally developed in our laboratory, against breast cancer; determine how they would potentiate the effectiveness of ATRA as well as study the molecular mechanisms involved. Novel RAMBAs (VN/14-1, VN/50-1, VN/66-1 and VN/69-1), structural analogs of ATRA/13-cis-retinoic acid, inhibited ATRA metabolism in hormone dependent MCF-7 cells and T47D cells; and microsomes with IC50 values in nanomolar range as determined by HPLC analysis. RAMBAs (0.0001--10 muM) had dose dependent antiproliferative action, suggesting that they have retinoidal activity as well. VN/50-1 and VN/14-1 enhanced ATRA's antiproliferative action in MCF-7 cells. RAMBAs induced differentiation in these cell lines as determined by analysis of differentiation markers cytokeratin 8/18 and E-cadherin. Induction of apoptosis by RAMBAs was determined by TUNEL assay and Western blotting of apoptosis related proteins. Cell cycle analysis indicated that RAMBAs arrest cells in the G1 phase and reduce cells in the S phase. RAMBAs reduced the expression of Cyclin D1 in these cell lines. VN/14-1 like ATRA increased the expression of estrogen receptor-alpha in MCF-7 cells. VN/14-1 besides being a potent RAMBA, has pleiotropic role, is well tolerated and significantly suppressed MCF-7 tumor growth (∼90.35% vs. control, p < 0.0005; at 66.0 mumole/kg/day dose) in female ovariectomized nude mice. Promising RAMBAs endowed with multiple biological activities should be suitable for further clinical investigations for chemoprevention and therapy of breast cancer.
Clinical Practice Guideline for Utilizing Sugammadex in Reversal of Neuromuscular Blocking AgentsHansen, Karissa; Pellegrini, Joseph (2019-05)Background: Residual paralysis is ongoing presence of muscle weakness postoperatively following the administration of a neuromuscular blocker and subsequent reversal agent during the intraoperative period. Presence of residual neuromuscular blockade postoperatively has been associated with increased mortality and morbidity, low oxygenation, and respiratory complications. Recent studies have shown incidences of residual neuromuscular blockade ranging from 16 to 60 percent. Local Problem: A medium sized hospital in Maryland reported postoperative complications associated with residual paralysis. Increased side effects such as muscle weakness, increased length of stay in Post Anesthesia Care Unit, and delay in discharge may be due to the lack of guidelines for reversal of non-depolarizing neuromuscular blockers. A meeting with institutional key stakeholders identified the need for a guideline for the use of sugammadex in prevention of residual paralysis. Development of CPG: The focus of this project was to develop a Clinical Practice Guideline for the use of sugammadex in the prevention of residual paralysis for high risk patients and in emergent situations such as cannot intubate, cannot ventilate scenarios. A literature review was conducted to support evidence for the Clinical Practice Guideline, gathered data was presented to the key stakeholders. The project proposal was then submitted to the University of Maryland, Institutional Review Board and granted a Non-Human Subjects determination. The quality of the Clinical Practice Guideline was assessed by institutional key stakeholder and analyzed using the AGREE II tool and then presented to the entire anesthesia department for further evaluation. Adjustments to the Clinical Practice Guideline were made following departmental feedback and a final Clinical Practice Guideline along with algorithms were developed for this project and were distributed throughout the perioperative arena. A further assessment was done by the department using Practitioner Feedback Questionnaires. All data collected from the AGREE II tool and the Practitioner Feedback Questionnaires were synthesized, analyzed, and evaluated. The final project manuscript was submitted to the University of Maryland School of Nursing Doctorate of Nursing Practice committee for review. Results: The results of the final AGREE II Tool were 100% across the 6 domains and for the overall assessment. Each appraiser had a total score of 161/161 points and an overall of 322/322 points. The anesthesia providers, the end users of the guideline, evaluated the Clinical Practice Guideline using the Practitioner Feedback Questionnaires. Majority of anesthesia providers felt the guideline should be approved for practice (95.5%) and felt if the guideline was approved, they would use it in their own practice (100%) and would apply the recommendations to their patients (100%). This analysis demonstrated buy-in and acceptance of the Clinical Practice Guideline by the department. Conclusion: Study results indicate sugammadex compared to current reversal, neostigmine, is safe and effective in the reversal of neuromuscular blocking agents and reduces adverse events and undesirable side effects. The approval of the Clinical Practice Guideline can change clinical practice and improve patient care. A standardized approach for reversal of neuromuscular blockade with the use of sugammadex will decrease the incidence of residual paralysis in this institution.